电子药盒辅助自我给药与标准直接观察治疗用于埃塞俄比亚结核病服药依从性和治疗结局的多中心随机对照试验方案
本研究为在埃塞俄比亚开展的多中心、开放标签、优效性、实效性-实施性混合、混合方法、两臂随机对照试验,计划纳入144例药物敏感肺结核门诊患者,比较电子药盒辅助自我给药与标准直接观察治疗对服药依从性和痰菌阴转的影响,并评估可用性、可接受性和成本效果。
要点
- 电子药盒辅助自我给药可能提高结核病服药依从性,但需本地证据支持。
- 主要结局为服药依从性和强化期痰菌阴转,用尿检和液体培养确认。
- 研究将评估干预的可用性、可接受性和成本效果,关注患者尊严与经济福祉。
核心结论
- 该研究旨在确定电子药盒辅助自我给药是否在不影响患者尊严和经济福祉的情况下改善结核病服药依从性和治疗结局。
研究设计与样本
- 多中心、随机、对照、开放标签、优效性、实效性-实施性混合、混合方法、两臂试验。
- 计划纳入144例新发或既往治疗、细菌学确认、药物敏感肺结核门诊患者,计划开始标准6个月一线抗结核方案。
- 干预组72例接受15天HRZE固定剂量组合疗法于evriMED500药物事件提醒监测装置中自我给药,对照组72例接受标准面对面直接观察治疗。
- 两臂均随访整个2个月强化期。
关键数值与推荐
- 主要结局为服药依从性和痰菌阴转;依从性计算为干预组(药片计数)与DOT组(直接观察)漏服剂量的患者比例,并通过IsoScreen尿异烟肼试验和八项Morisky服药依从性量表自我报告进一步确认。
- 痰菌阴转定义为干预组与DOT组强化期后涂片转阴的患者比例,并通过强化期前后BACTEC MGIT结核液体培养进一步确认。
- 治疗前后MGIT药物敏感性试验将确定抗结核药物耐药是否影响培养阴转。
- 次要结局包括其他临床结局(治疗未完成、死亡或失访)、成本效果(个体和社会成本与质量调整生命年)以及患者和提供者对干预的接受性和可用性。
临床怎么用
- 若证实有效,电子药盒辅助自我给药可作为结核病直接观察治疗的替代方案,减少患者往返医疗机构负担。
- 实施时需结合药片计数、尿检和自我报告综合评估服药依从性。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To address the multifaceted challenges associated with tuberculosis (TB) in-person directly observed therapy (DOT), the World Health Organization recently recommended that countries maximize the use of digital adherence technologies. Sub-Saharan Africa needs to investigate the effectiveness of such technologies in local contexts and proactively contribute to global decisions around patient-centered TB care. This study aims to evaluate the effectiveness of pillbox-enabled self-administered therapy (SAT) compared to standard DOT on adherence to TB medication and treatment outcomes in Ethiopia. It also aims to assess the usability, acceptability, and cost-effectiveness of the intervention from the patient and provider perspectives. METHODS: This is a multicenter, randomized, controlled, open-label, superiority, effectiveness-implementation hybrid, mixed-methods, two-arm trial. The study is designed to enroll 144 outpatients with new or previously treated, bacteriologically confirmed, drug-sensitive pulmonary TB who are eligible to start the standard 6-month first-line anti-TB regimen. Participants in the intervention arm (n = 72) will receive 15 days of HRZE-isoniazid, rifampicin, pyrazinamide, and ethambutol-fixed-dose combination therapy in the evriMED500 medication event reminder monitor device for self-administration. When returned, providers will count any remaining tablets in the device, download the pill-taking data, and refill based on preset criteria. Participants can consult the provider in cases of illness or adverse events outside of scheduled visits. Providers will handle participants in the control arm (n = 72) according to the standard in-person DOT. Both arms will be followed up throughout the 2-month intensive phase. The primary outcomes will be medication adherence and sputum conversion. Adherence to medication will be calculated as the proportion of patients who missed doses in the intervention (pill count) versus DOT (direct observation) arms, confirmed further by IsoScreen urine isoniazid test and a self-report of adherence on eight-item Morisky Medication Adherence Scale. Sputum conversion is defined as the proportion of patients with smear conversion following the intensive phase in intervention versus DOT arms, confirmed further by pre-post intensive phase BACTEC MGIT TB liquid culture. Pre-post treatment MGIT drug susceptibility testing will determine whether resistance to anti-TB drugs could have impacted culture conversion. Secondary outcomes will include other clinical outcomes (treatment not completed, death, or loss to follow-up), cost-effectiveness-individual and societal costs with quality-adjusted life years-and acceptability and usability of the intervention by patients and providers. DISCUSSION: This study will be the first in Ethiopia, and of the first three in sub-Saharan Africa, to determine whether electronic pillbox-enabled SAT improves adherence to TB medication and treatment outcomes, all without affecting the inherent dignity and economic wellbeing of patients with TB. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04216420. Registered on 2 January 2020.
引用
- Manyazewal T, Woldeamanuel Y, Holland DP, et al. Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial. Trials. 2020. PMID: 32370774. doi:10.1186/s13063-020-04324-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。